C22orf42 siRNA (h): sc-75442



The Power to Question

BACKGROUND

Chromosome 22 contains over 500 genes and about 49 million bases. Being the second smallest human chromosome, 22 contains a surprising variety of interesting genes. Phelan-McDermid syndrome, neurofibromatosis type 2 and autism are associated with chromosome 22. A schizophrenia susceptibility locus has been identified on chromosome 22 and studies show that 22q11 deletion symptoms include a high incidence of schizophrenia. Transloacations between chromosomes 9 and 22 may lead to the formation of the Philadelphia chromosome and the subsequent production of the novel fusion protein, Bcr-Abl, a potent cell proliferation activator found in several types of leukemia. The LOC150297 gene product has been provisionally designated LOC150297 pending further characterization.

REFERENCES

- 1. Gilbert, F. 1998. Disease genes and chromosomes: disease maps of the human genome. Chromosome 22. Genet. Test. 2: 89-97.
- Schwab, S.G., et al. 1999. Chromosome 22 workshop report. Am. J. Med. Genet. 88: 276-278.
- Tsilchorozidou, T., et al. 2004. Constitutional rearrangements of chromosome 22 as a cause of neurofibromatosis 2. J. Med. Genet. 41: 529-534.
- Arinami, T. 2006. Analyses of the associations between the genes of 22q11 deletion syndrome and schizophrenia. J. Hum. Genet. 51: 1037-1045.
- Paylor, R., et al. 2006. TBX1 haploinsufficiency is linked to behavioral disorders in mice and humans: implications for 22q11 deletion syndrome. Proc. Natl. Acad. Sci. USA 103: 7729-7734.
- Zheng, X., et al. 2006. Bcr and its mutants, the reciprocal t(9;22)-associated Abl/Bcr fusion proteins, differentially regulate the cytoskeleton and cell motility. BMC Cancer 6: 262.
- 7. Ahronowitz, I., et al. 2007. Mutational spectrum of the NF2 gene: a metaanalysis of 12 years of research and diagnostic laboratory findings. Hum. Mutat. 28: 1-12.
- Hay, B.N. 2007. Deletion 22q11: spectrum of associated disorders. Semin. Pediatr. Neurol. 14: 136-139.

CHROMOSOMAL LOCATION

Genetic locus: C22orf42 (human) mapping to 22q12.3.

PRODUCT

C22orf42 siRNA (h) is a pool of 2 target-specific 19-25 nt siRNAs designed to knock down gene expression. Each vial contains 3.3 nmol of lyophilized siRNA, sufficient for a 10 μ M solution once resuspended using protocol below. Suitable for 50-100 transfections. Also see C22orf42 shRNA Plasmid (h): sc-75442-SH and C22orf42 shRNA (h) Lentiviral Particles: sc-75442-V as alternate gene silencing products.

For independent verification of C22orf42 (h) gene silencing results, we also provide the individual siRNA duplex components. Each is available as 3.3 nmol of lyophilized siRNA. These include: sc-75442A and sc-75442B.

STORAGE AND RESUSPENSION

Store lyophilized siRNA duplex at -20 $^{\circ}$ C with desiccant. Stable for at least one year from the date of shipment. Once resuspended, store at -20 $^{\circ}$ C, avoid contact with RNAses and repeated freeze thaw cycles.

Resuspend lyophilized siRNA duplex in 330 μ l of the RNAse-free water provided. Resuspension of the siRNA duplex in 330 μ l of RNAse-free water makes a 10 μ M solution in a 10 μ M Tris-HCl, pH 8.0, 20 mM NaCl, 1 mM EDTA buffered solution.

APPLICATIONS

C22orf42 siRNA (h) is recommended for the inhibition of C22orf42 expression in human cells.

SUPPORT REAGENTS

For optimal siRNA transfection efficiency, Santa Cruz Biotechnology's siRNA Transfection Reagent: sc-29528 (0.3 ml), siRNA Transfection Medium: sc-36868 (20 ml) and siRNA Dilution Buffer: sc-29527 (1.5 ml) are recommended. Control siRNAs or Fluorescein Conjugated Control siRNAs are available as 10 μ M in 66 μ l. Each contain a scrambled sequence that will not lead to the specific degradation of any known cellular mRNA. Fluorescein Conjugated Control siRNAs include: sc-36869, sc-44239, sc-44240 and sc-44241. Control siRNAs include: sc-37007, sc-44230, sc-44231, sc-44232, sc-44234, sc-44235, sc-44236, sc-44237 and sc-44238.

GENE EXPRESSION MONITORING

C22orf42 (C-4): sc-515009 is recommended as a control antibody for monitoring of C22orf42 gene expression knockdown by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000) or immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500).

To ensure optimal results, the following support reagents are recommended: 1) Western Blotting: use m-lgG κ BP-HRP: sc-516102 or m-lgG κ BP-HRP (Cruz Marker): sc-516102-CM (dilution range: 1:1000-1:10000), Cruz MarkerTM Molecular Weight Standards: sc-2035, UltraCruz[®] Blocking Reagent: sc-516214 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluorescence: use m-lgG κ BP-FITC: sc-516140 or m-lgG κ BP-PE: sc-516141 (dilution range: 1:50-1:200) with UltraCruz[®] Mounting Medium: sc-24941 or UltraCruz[®] Hard-set Mounting Medium: sc-359850.

RT-PCR REAGENTS

Semi-quantitative RT-PCR may be performed to monitor C22orf42 gene expression knockdown using RT-PCR Primer: C22orf42 (h)-PR: sc-75442-PR (20 μ l). Annealing temperature for the primers should be 55-60° C and the extension temperature should be 68-72° C.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.

Santa Cruz Biotechnology, Inc. 1.800.457.3801 831.457.3800 fax 831.457.3801 **Europe** +00800 4573 8000 49 6221 4503 0 **www.scbt.com**